Impact of p-tau181 and p-tau217 levels on enrollment for randomized clinical trials and future use of anti-amyloid and anti-tau drugs
Expert Rev Neurother
.
2020 Dec;20(12):1211-1213.
doi: 10.1080/14737175.2020.1841637.
Epub 2020 Dec 2.
Authors
Serge Gauthier
1
,
Joseph Therriault
1
,
Tharick Pascoal
1
,
Pedro Rosa-Neto
1
Affiliation
1
McGill Center for Studies in Aging , Montreal, QC, Canada.
PMID:
33094676
DOI:
10.1080/14737175.2020.1841637
No abstract available
Keywords:
Alzheimer’s disease; Plasma biomarker; diagnosis; p-tau181; screening.
Publication types
Editorial
Research Support, Non-U.S. Gov't